Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients

Medical Oncology

Volumn 21, Issue 1, 2004, Pages 9-19

  Kangarloo, Shahbal B ^a   Gangopadhyay, Suman B ^a   Syme, Rachel M ^a   Wolff, Johannes E A ^b   Glück, Stefan ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Klinik St Hedwig   (Germany)

^c TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Chemoprotectants; Combination chemotherapy; Drug interactions; Platinum drugs

Indexed keywords

CARBOPLATIN; CISPLATIN; MESNA; OXAZAPHOSPHORINE DERIVATIVE; PLATINUM;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HUMAN; IN VITRO STUDY; INFANT; MALE; PRIORITY JOURNAL; ULTRAFILTRATION;

EID: 1842833446     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/mo:21:1:09     Document Type: Article

References (33)

1. Brock N, Pohl J, Stekar J, Scheef W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 1982;18(12):1377-1387.
2. Shaw IC, Graham MI. Mesna a short review. Cancer Treat Rev 1987;14(2):67-86.
3. Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57(3):293-308.
4. Howe-Grant ME, Lippard SJ. Aqueous platinum (II) chemistry; binding to biological molecules. In: Helmut S (ed). Metal Ions in Biological Systems. New York: Marcel Dekker Inc.; 1980. pp. 63-125.
5. Wolff JE, Egeler RM, Anderson R, Ujack E, Iceton S, Coppes MJ. Mesna inactivates platinum agents in vitro. Antican Res 1998;18(6A):4077-4081.
6. Boven E, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 2002;38(8):1148-1156.
7. Sadowitz PD, et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 2002;30(2):183-190.
8. Dorr RT, Lagel K. Interaction between cisplatin and mesna in mice. J Cancer Res Clin Oncol 1989;115(6):604-605.
9. Hausheer FH, et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first-and second-generation protecting agents. Sem Oncol 1998;25(5):584-599.
10. Wils J, et al. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Antican Drugs 1999;10(3):257-261.
11. Culine S, Theodore C, Bekradda M, Farhat F, Terrier-Lacombe MJ, Droz JP. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol 1997;20(2):184-188.
12. Polyzos A, et al. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin- cyclophosphamide. J Chemother 1999;11(2):144-149.
13. Graziano SL, et al. A randomized phase II study of ifosfamide/mesna/ cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996;14(2-3):315-329.
14. Fetscher S, et al. Standard-and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. Ann Oncol 1999;10(5):605-607.
15. Gerke P, Filejski W, Robins HI, Wiedemann GJ, Steinhoff J. Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. J Cancer Res Clin Oncol 2000;126(3):173-177.
16. Edmonson JH, et al. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest 2001;19(6):597-602.
17. Meyer WH, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude children's research hospital os-91 trial. J Clin Oncol 2001;19(1):171-182.
18. Gangopadhyay SB, Roendigs A, Kangarloo SB, Krebs B, Wolff JE. Cellular accumulation determines the activity of three novel tricyclic platinum agents. Antican Res 2001;21(3B):2039-2043.
19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Dekker, 1982.
20. James CA, Mant TG, Rogers HJ. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 1987;23(5):561-568.
21. Goren MP, et al. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 1998;16(2):616-621.
22. Ormstad K, Uehara N. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett 1982;150(2):354-358.
23. Leeuwenkamp OR, van der Vijgh WJ, Neijt JP, Pinedo HM. Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP. Cancer Chemother Pharmacol 1990;27(2):111-114.
24. Obrocea MM, et al. In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine. Oncol Rep 1998;5(6):1493-1498.
25. Peng B, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 1997;33(11):1823-1828.
26. Newell DR, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 1993;11(12):2314-2323.
27. Leeuwenkamp OR, Neijt JP, van der Vijgh WJ, Pinedo HM. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate. Eur J Cancer 1991;27(10):1243-1247.
28. Vermorken JB, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986;39(2):136-144.
29. Barnham KJ, Djuran MI, del Socorro Murdoch P, Ranford JD, Sadler PJ. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorgan Chem 1996;35(4):1065-1072.
30. Natarajan G, Malathi R, Holler E. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol 1999;58(10):1625-1629.
31. Tonda ME, Heideman RL, Petros WP, Friedman HS, Murry DJ, Rodman JH. Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemother Pharmacol 1996;38(5):395-400.
32. Murry DJ. Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy 1997;17(5 Pt 2):140S-145S.
33. Notari RE. Biopharmaceutics and clinical pharmacokinetics: an introduction. 4th rev. and expand ed. New York: Dekker, 1987.